Nkarta, Inc.
NKTXHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeNkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Valued at $231.3M, NKTX is a micro-cap name in its sector. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis.
Market Cap
$231.3M
Beta
0.97
P/E (TTM)
—
P/E (Fwd)
-1.84
EPS (TTM)
$-1.59
EPS (Fwd)
$-1.75
ROE
-38.8%
ROA
-19.6%
Cash
$182.8M
Total Debt
$73.5M
Free CF
-$55.1M
52W Change
44.5%
Annual Financials
Cash vs Debt
Where NKTX stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, NKTX finished 6.95% above its 150-day moving average ($2.59) and 13.99% above its 200-day moving average ($2.43). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NKTX overbought or oversold?
At the September 3, 2026 close, NKTX's RSI(14) was 71.8, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $182.8M in cash comfortably exceeding the $73.5M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$55.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -38.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With cash comfortably exceeding debt, NKTX has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing NKTX.